Strong momentum following initial launch

Following its successful pilot launch in March 2025 in Sweden, the iOS app was rolled out in May across Austria, Denmark, Finland, Germany, Ireland, Luxembourg, Norway, Switzerland, and the United Kingdom. The overwhelmingly positive feedback from users in these markets has laid the groundwork for further expansion. As of today, mylife Loop on iOS is also available in Australia, Belgium, Czechia, France, Italy, the Netherlands, New Zealand, Poland, and Spain.

Our goal is to simplify life for people with diabetes. The very positive feedback on our integrated, intuitive AID system, mylife Loop, shows that it is truly making a difference,

explains Sébastien Delarive, Chief Business Officer Diabetes Care at Ypsomed. 

Professor Roman Hovorka, Director CamDiab and Professor of Metabolic Technology at the Institute of Metabolic Science and Department of Paediatrics at the University of Cambridge, says:

We are thrilled to bring the mylife CamAPS FX app to iOS users across Europe and beyond. This launch marks a major step in making advanced, adaptive diabetes technology more accessible and convenient.

Seamless integration with leading CGM sensors 

mylife CamAPS FX on iOS is now fully compatible with Continuous Glucose Monitoring (CGM) sensors including the FreeStyle Libre 3 and FreeStyle Libre 3 Plus from Abbott, and the Dexcom G6. This ensures that users can benefit from reliable, real-time glucose data using their preferred CGM device. 

Enhanced data sharing via mylife Cloud 

Coinciding with this rollout, the mylife Cloud data sharing function is now available via the mylife CamAPS FX app in all countries for all operating systems. This feature enables secure sharing of therapy and glucose data with healthcare professionals and caregivers, enhancing support and remote diabetes management. 

About mylife Loop 

mylife Loop is a modular AID solution for the treatment of type 1 diabetes. The adaptive mylife CamAPS FX algorithm runs on the personal smartphone and is approved for people with type 1 diabetes aged one year and older*, depending on the sensor used for continuous glucose monitoring. It is the only algorithm indicated for pregnant women with type 1 diabetes*. mylife Loop integrates the mylife YpsoPump insulin pump and a compatible sensor for continuous glucose monitoring, including FreeStyle Libre 3 or FreeStyle Libre 3 Plus from Abbott or Dexcom G6 from Dexcom. mylife Loop is marketed in most European countries, Canada, Australia and New Zealand. Further information and details can be found at www.mylife-diabetes-care.com/loop. 

CamDiab Ltd  
CamDiab Ltd is a digital health and personalized medicine company focused on the design, development, and commercialization of its world leading, interoperable CamAPS FX hybrid closed loop app. The CamAPS FX algorithm is designed to be adaptive and self-learning, linked to a compatible continuous glucose monitoring device and a compatible insulin pump, to autonomously compute and direct insulin delivery to maintain tight glycemic control. Since its founding in 2019, its mission has been to help people with type 1 diabetes and their families live better lives. For further information, visit www.camdiab.com or follow CamDiab Ltd and its products on Facebook, LinkedIn, and Twitter@CamAPS_FX.

*Depending on local indication. 

mylife and YpsoPump are registered trademarks of Ypsomed AG in several countries. // CamAPS is a registered trademark of CamDiab Ltd. // Dexcom and Dexcom G6 are registered trademarks of Dexcom, Inc. in the United States and/or other countries // FreeStyle, Libre, and related brand marks are marks of Abbott and used with permission // iPhone is trademark of Apple Inc., registered in the US and other countries and regions. // Other trademarks are the property of their respective owners.